Interdict develops small molecule drugs, called Interdictors™, that inhibit protein synthesis by targeting the nascent polypeptide interacting with the ribosome. This proprietary platform generates orally bioavailable compounds designed to address historically undruggable targets in oncology and neurodegeneration. The company is advancing a pipeline focused on developing treatments for MYC-dependent cancers and other serious diseases.
Funding
Funding not disclosed
Founders
Product
Problem
Many disease-causing proteins have been considered "undruggable" due to their structural properties or lack of accessible binding sites, leaving patients with limited or no treatment options for diseases like cancer, rare genetic disorders, neurodegenerative conditions, and autoimmune disorders.
Solution
The company has developed a small molecule therapeutics platform designed to target these historically undruggable proteins. This platform enables the creation of novel drug candidates that can effectively bind to and modulate the activity of previously inaccessible targets. By overcoming the limitations of traditional drug discovery approaches, the platform aims to unlock new therapeutic avenues for a wide range of diseases, offering the potential for improved patient outcomes where existing treatments are inadequate.
Target Audience
The primary target audience includes pharmaceutical companies, biotechnology firms, and research institutions focused on developing novel therapeutics for oncology, rare diseases, neurodegeneration, and autoimmunity.
Features
- Proprietary small molecule design and optimization techniques for targeting challenging protein structures
- Screening assays to identify compounds with high affinity and selectivity for undruggable targets
- Computational modeling and structural biology to guide drug design and predict efficacy
- Medicinal chemistry capabilities to optimize drug properties, such as bioavailability and target engagement